-+ 0.00%
-+ 0.00%
-+ 0.00%

Eling Pharmaceutical (002603.SZ) subsidiary's application for clinical trial of bone and joint health granule drugs was accepted

Zhitongcaijing·10/22/2026 09:41:19
Listen to the news

Zhitong Finance App News, Eling Pharmaceutical (002603.SZ) issued an announcement. Beijing Eling Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Notice of Acceptance” approved and issued by the State Drug Administration on October 21, 2026, and the clinical trial application for a new bone and joint granule drug was accepted. The intended functions of bone and joint health granules are: supplement kidney and bone health, activate blood circulation, and relieve muscle pain.